Stigmasterol and all the synthesized derivatives were screened against non-tumorigenic epithelial cell lines established from breast tissue (MCF-12 A), hormone receptor-positive breast cancer (MCF-7) and triple-negative breast cancer (HCC70) cell lines. This evidence concerns the gene NR4A1 and triple-negative breast carcinoma.